Biomea Fusion (BMEA) to Release Quarterly Earnings on Tuesday

Biomea Fusion (NASDAQ:BMEA - Get Free Report) is anticipated to announce its earnings results before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($1.00) per share for the quarter.

Biomea Fusion Trading Down 3.8 %

Shares of Biomea Fusion stock traded down $0.11 on Tuesday, reaching $2.69. 329,231 shares of the company were exchanged, compared to its average volume of 921,862. The company has a market capitalization of $97.30 million, a price-to-earnings ratio of -0.67 and a beta of -0.26. Biomea Fusion has a one year low of $2.35 and a one year high of $16.29. The company has a 50-day moving average of $3.44 and a 200 day moving average of $6.13.

Wall Street Analyst Weigh In

BMEA has been the subject of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Biomea Fusion in a research report on Monday. D. Boral Capital reissued a "buy" rating and set a $16.00 price target on shares of Biomea Fusion in a research report on Wednesday, March 19th. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $29.18.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.